Form 4: Cognition Therapeutics CMO Anthony Caggiano Reports Significant Stock Acquisition from PSU Vesting

Cognition Therapeutics' Chief Medical Officer, Anthony Caggiano, reported the acquisition of 65,000 shares of common stock through the vesting of performance stock units, alongside a disposition of 20,281 shares for tax withholding.

Summary

• Anthony Caggiano, Chief Medical Officer of Cognition Therapeutics Inc. (CGTX), acquired 65,000 shares of common stock on July 29, 2025.
• The acquisition was due to the vesting of performance stock units (PSUs) granted on February 14, 2024, with 50% of the total shares subject to the PSUs vesting.
• Concurrently, 20,281 shares were disposed of on July 29, 2025, at a price of $0.6702 per share.
• This disposition represents shares withheld by Cognition Therapeutics to cover tax withholding obligations related to the PSU vesting.
• Following these transactions, Anthony Caggiano beneficially owns 463,273 shares of common stock directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The acquisition of shares through PSU vesting indicates the achievement of performance goals, which is a positive operational sign. The disposition for tax withholding is a standard, expected event and does not reflect negative sentiment towards the company.

Positives

• The acquisition of 65,000 shares through PSU vesting indicates the achievement of performance goals, which is a positive sign for the company's operational progress.
• The vesting of PSUs aligns the executive's interests with shareholder value, as these are performance-based awards.

Negatives

• A disposition of 20,281 shares occurred to cover tax withholding obligations, reducing the executive's direct beneficial ownership.

Future Outlook

NA

Industry Context

This filing details an executive's compensation-related stock transaction, which is a routine event in publicly traded companies across all industries. It does not provide broader industry trends or competitive insights.

Stakeholder Impact

• Shareholders: The vesting of PSUs for a key executive like the Chief Medical Officer can be seen as a positive signal regarding the company's progress towards its strategic and operational goals, potentially aligning executive incentives with shareholder value. The disposition for tax purposes is a routine event and has minimal direct impact on other shareholders.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (PSU vesting and tax-related share disposition). It does not provide new information about the company's financial performance, strategic direction, or market position that would warrant a change in investment recommendation. The transaction is an expected part of executive compensation and does not indicate a significant shift in company fundamentals or outlook. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide a basis for a 'buy' or 'sell' decision.

Keywords

Cognition Therapeutics, CGTX, Anthony Caggiano, Chief Medical Officer, SEC Form 4, Insider Trading, Stock Vesting, Performance Stock Units, PSUs, Executive Compensation, Share Ownership